CAR-T Cell Therapy Market Size, Share & Industry Analysis, By Drug Type (Axicabtagene Ciloleucel (Yescarta), Brexucabtagene Autoleucel (Tecartus), Ciltacabtagene Autoleucel (Carvykti), Idecabtagene Vicleucel (Abecma), Lisocabtagene Maraleucel (Breyanzi), Tisagenlecleucel (Kymriah), and Others), By Indication (Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma, and Multiple Myeloma), By End-user (Hospitals and Oncology Treatment Centers), and Regional Forecast, 2024-2032

Last Updated: February 17, 2025 | Format: PDF | Report ID: FBI108455

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2023
Estimated Year	2024
Forecast Period	2024-2032
Historical Period	2019-2022
Growth Rate	CAGR of 12.5% from 2024-2032
Unit	Value (USD billion)
Segmentation	By Drug Type Axicabtagene Ciloleucel (Yescarta) Brexucabtagene Autoleucel (Tecartus) Ciltacabtagene Autoleucel (Carvykti) Idecabtagene Vicleucel (Abecma) Lisocabtagene Maraleucel (Breyanzi) Tisagenlecleucel (Kymriah) Others
	By Indication Acute Lymphoblastic Leukemia Non-Hodgkin Lymphoma Multiple Myeloma
	By End-user Hospitals Oncology Treatment Centers
	By Region North America (By Drug Type, By Indication, By End-user, By Country) U.S. Canada Europe (By Drug Type, By Indication, By End-user, By Country/Sub-region) Germany U.K. France Italy Spain Scandinavia Rest of Europe Asia Pacific (By Drug Type, By Indication, By End-user, By Country/Sub-region) China Japan India Australia Southeast Asia Rest of Asia Pacific Rest of the World (By Drug Type, By Indication, By End-user)